Workflow
Securities fraud
icon
Search documents
HIMS Deadline: HIMS Investors with Losses in Excess of $100K Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
Prnewswire· 2025-08-23 16:05
Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by August 25, 2025, to represent other class members [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the access to compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV and CIO on Behalf of Shareholders
GlobeNewswire News Room· 2025-08-23 15:04
Group 1 - Halper Sadeh LLC is investigating ZimVie Inc. for potential violations of federal securities laws related to its sale to an affiliate of ARCHIMED for $19.00 per share in cash [1] - City Office REIT, Inc. is under investigation for its sale to MCME Carell Holdings for $7.00 per share in cash [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DAY and NWE on Behalf of Shareholders
GlobeNewswire News Room· 2025-08-23 15:02
Group 1 - Halper Sadeh LLC is investigating Dayforce, Inc. for potential violations related to its sale to Thoma Bravo at $70.00 per share in cash [1] - NorthWestern Energy Group, Inc. is being investigated regarding its sale to Black Hills Corp. for 0.98 shares of Black Hills for each share of NorthWestern, resulting in NorthWestern shareholders owning approximately 44% of the combined company [2] - The firm may seek increased consideration for shareholders and additional disclosures concerning the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]
KLC INVESTOR NOTICE: Investor Files Class Action Lawsuit Against KinderCare Learning Companies, Inc. and Attorneys Announce Opportunity for Investors with Substantial Losses to Lead Investor Class Action Lawsuit
Prnewswire· 2025-08-23 14:15
SAN DIEGO, Aug. 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare's October 2024 initial public offering (the "IPO"), have until Monday, October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit.  Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424 (D. Or.), the KinderCare class action lawsuit charges KinderCare and certa ...
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS
GlobeNewswire News Room· 2025-08-23 13:45
Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged securities fraud related to misleading statements about its collaboration with Novo Nordisk and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations of the Lawsuit - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - It is alleged that the company failed to disclose the risks associated with its collaboration with Novo Nordisk, leading to a significant risk of termination of the partnership [2] - Novo Nordisk officially terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason, resulting in a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5] - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [5]
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Prnewswire· 2025-08-23 12:26
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 15, 2025 deadline [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - These misleading statements allegedly led to shareholders purchasing Capricor's securities at artificially inflated prices, resulting in damages when the true information became public [5]
SLP CLASS REMINDER: Suffer Losses on Your Simulations Plus, Inc. Investment? Contact BFA Law about the Securities Fraud Investigation (NASDAQ:SLP)
GlobeNewswire News Room· 2025-08-23 11:08
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit. Why Is Simulations Plus being Investigated?Simulations Plus is a software company that develops tools for modelin ...
FLYW CLASS REMINDER: Suffer Losses on Your Flywire Corporation Investment? Contact BFA Law before the September 23 Court Deadline (NASDAQ:FLYW)
GlobeNewswire News Room· 2025-08-23 11:08
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Flywire Corporation (NASDAQ: FLYW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Flywire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/flywire-corporation-class-action-lawsuit. Investors have until September 23, 2025, to ask the Court to b ...
SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)
GlobeNewswire News Room· 2025-08-23 11:08
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...
RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST)
GlobeNewswire News Room· 2025-08-23 11:08
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...